ScreenerHero

GLASGlass House Brands Inc.

Partial data
NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · glasshousebrands.com
8.010USD-20.22%Mkt Cap: 754.88M $P/E: —

Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States. It operates through three segments: Retail; Wholesale Biomass; and Cannabis-Related Consumer Packa…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$62.92BUSDP/E 24.4
TAK
Takeda Pharmaceutical Company Limited
$60.52BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.09BUSDP/E 65.9
HLN
Haleon plc
$40.68BUSDP/E 19.3
ZTS
Zoetis Inc.
$30.11BUSDP/E 11.9
ZOE
Zoetis Inc.
$28.32BUSDP/E 11.8
UTHR
United Therapeutics Corporation
$21.34BUSDP/E 17.8
VTRS
Viatris Inc.
$19.73BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.95BUSDP/E 114.9
NBIX
Neurocrine Biosciences, Inc.
$14.46BUSDP/E 20.8
IPN
Ipsen S.A.
$13.51BUSDP/E 24.4
ELAN
Elanco Animal Health Incorporated
$11.45BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.47BUSDP/E 30.7
KRK
Krka, d. d.
$8.71BUSDP/E 18.9
ALKS
Alkermes plc
$7.26BUSDP/E 113.9
HIMS
Hims & Hers Health, Inc.
$7.10BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$7.02BUSDP/E 42.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.79BUSDP/E 40.6
LNTH
Lantheus Holdings, Inc.
$6.53BUSDP/E 23.9
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0

Key Statistics

Company
Market Cap754.88M $
Enterprise Value1.08B $
Revenue (TTM)177.68M $
Gross Profit76.96M $
Net Income (TTM)-29.66M $
Revenue/Share2.130 USD
Last Price8.010 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees357
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)35.96
PEG—
EV/EBITDA-99.90
EV/Revenue6.10
P/S4.81
P/B10.50
EPS (TTM)-0.60
EPS (Forward)0.27
52W Range
4.95034% of range13.93
52W High13.93 USD
52W Low4.950 USD
Profitability
Gross Margin42.29%
Oper. Margin-35.42%
EBITDA Margin-6.11%
Profit Margin-16.30%
ROE-40.11%
ROA-9.31%
Growth
Revenue Growth-9.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF11.45M $
CapEx (TTM)27.18M $
FCF Margin-14.71%
FCF Yield-3.46%
Net Debt50.62M $
Net Debt/EBITDA-4.66
Balance Sheet
Debt/Equity1.01
Current Ratio1.85
Quick Ratio0.79
Book Value/Sh0.9080 USD
Cash/Share0.2880 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)16.33 USD
Upside (mean)+103.9%
Target Range16.00 USD – 17.00 USD
$16.00+103.9% to mean$17.00
# Analysts3
Ownership
Shares Out.83.44M
Float63.72M
Insiders7.87%
Institutions7.29%
Short Interest
Short Ratio0.2d
Short % Out.0.16%
Shares Short78.58K
Technical
SMA 5011.51 (-30.4%)
SMA 2009.041 (-11.4%)
Beta0.51
S&P 52W Chg19.23%
Avg Vol (30d)394.96K
Avg Vol (10d)349.03K
Technical Indicators
RSI (14)36.6
MACD-0.3825
MACD Signal-0.1978
MACD Hist.-0.1847
BB Upper13.16 USD
BB Middle11.49 USD
BB Lower9.826 USD
BB Width29.01%
ATR (14)0.7047 USD
Vol Ratio (20d)1.05x